Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)
Disease-free survival · People with squamous cell carcinoma of the oral cavity or oropharynx
It is very uncertain whether tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… changes disease-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (very low certainty).
1 finding from 1 review
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes40 to 60 months · Gefitinib + radiotherapy (oral cavity)HR 1.51 [0.61, 3.71]1 study · 60 participantsVery low